Advocacy Partnership

Friday 3 September 2010

Tuberculosis (TB) can usually be treated with a course of four standard, or first-line, anti-TB drugs. However, if these drugs are misused or mismanaged, multidrug-resistant TB (MDR-TB) can develop. MDR-TB is a specific form of TB, resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs. MDR-TB takes longer to treat with second-line drugs, which are more expensive and have more side-effects.

Advocacy when effectively planned and executed can help shape the policy priorities and leverage much greater levels of financial support, in particular public sector finance.

The Advocacy Partnership intends to help build the advocacy capacity for TB and MDR-TB so that greater weight is brought to bear on those decision-makers who have the power to influence change.

Advocacy Partnership

The Advocacy Partnership is a UK non-governmental organisation with the specific aim of building the capacity of civil society advocates to impact TB and MDR-TB globally.

The main activity of the Advocacy Partnership lies around its Building Citizen Advocacy Project:

News update


TB community advocacy introduced to the mining community in South Africa

The Aurum Institute, has taken a lead in establishing TB Community Advisory Groups (CAG), made up of local community members, church leaders, politicians (ward councillors), community development workers, media representative (both print and radio) and decision makers from district department of health to advise in TB community interventions. More Information.


The Advocacy Partnership is an NGO member of the Stop TB Partnership.

The Advocacy Partnership is a member of the UK Coalition to Stop TB.

The Advocacy Partnership is a UK registered charity number 1123877 and company limited by guarantee, number 6410272.

Links:

Copyright © 2010 Advocacy Partnership

Web Design by Ferrer Consulting Ltd